# NAPS2 Data Management and Statistics Core

> **NIH NIH U19** · WASHINGTON UNIVERSITY · 2021 · $989,861

## Abstract

ABSTRACT: NAPS2 DATABASE MANAGEMENT AND STATISTICS (DMS) CORE
The Data Management and Statistics (DMS) Core of the North American Prodromal Synucleinopathy
Consortium on RBD, Stage 2 (NAPS2) will serve as both a collaborator and a valuable resource for the
Cores and the Project focused on predicting phenoconversion. The DMS Core will assist in the application of
appropriate statistical and methodological techniques as well as leading and collaborating data analysis and
report preparations for all Cores and the Project. We will work with the Administrative and Clinical Cores
and study sites to ensure target enrollment is achieved and the data collected is scrutinized with the highest
quality control (QC) standards which include training on Part 11 compliance systems and procedures, data
monitoring, queries and cleaning. We will work with the other Cores to integrate their collected data, providing
additional QC through bi-annual data freezes. The DMS Core’s assistance is specifically needed for analysis of
associations among longitudinal growth/decline and symptomatic conversion patterns of all disease markers.
The DMS Core is imperative for providing a central standard data set, both retrospectively from the existing
NAPS1 data, and prospectively collected data in NAPS2 which will avoid study inconsistencies and varying
approaches. By using this centralized and standardized approach and providing expertise in deep learning
analysis across cores and machine learning, we can offer the highest quality data which in turn will create the
most reliable results for the Project. The NAPS2 DMS Core will act as a resource to all investigators, including
those outside of the NAPS2 Consortium to assist with reliable and reproducible data analysis. It is the mission
of the DMS Core to enhance and support the research objectives of the NAPS2 Consortium by providing timely
and reliable data management and appropriate analytic expertise which will ultimately lead to optimal trial
planning and future clinical trials for synucleinopathies in RBD participants.

## Key facts

- **NIH application ID:** 10187089
- **Project number:** 1U19AG071754-01
- **Recipient organization:** WASHINGTON UNIVERSITY
- **Principal Investigator:** CHENGJIE XIONG
- **Activity code:** U19 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $989,861
- **Award type:** 1
- **Project period:** 2021-08-01 → 2026-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10187089

## Citation

> US National Institutes of Health, RePORTER application 10187089, NAPS2 Data Management and Statistics Core (1U19AG071754-01). Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/grant/nih/10187089. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*